Goldman Sachs maintains neutral rating on HealthEquity stock

Goldman Sachs reiterated a Neutral rating on HealthEquity (HQY) with a $104 price target following Q1 FY26 results, citing strong financial health with a 65% gross profit margin and revised revenue growth forecasts to 9.3% and EPS to $3.69. While Q1 performance showed strength with revenue of $331.9 million and EPS of $0.97 exceeding expectations, analysts noted moderating organic HSA account growth trends and did not incorporate potential policy changes into their models, contrasting with Citizens JMP raising their price target to $117 based on the company's strong financial performance and positive outlook.

Analysis

HealthEquity (NASDAQ: HQY) reported a strong first quarter for fiscal year 2026, with revenue reaching $331.9 million, a 15% year-over-year increase that surpassed analyst projections of $322.58 million, and earnings per share of $0.97, exceeding the forecasted $0.82. The company's adjusted EBITDA grew 19% year-over-year to $140.2 million, and its gross profit margin improved to 68% from 65% in the prior year, reflecting effective cost management and strong financial health, further supported by InvestingPro data indicating liquid assets exceed short-term obligations and a 65% gross profit margin. Following these results, Goldman Sachs reiterated a Neutral rating with a $104 price target, revising its fiscal year 2026 revenue growth forecast for HQY to 9.3% (from 8.5%) and EPS to $3.69 (from $3.63), citing improved gross margin trajectories in Service and Interchange segments. However, this Neutral stance is maintained due to concerns over a slowing organic HSA account growth trend, attributed to macroeconomic uncertainty and hiring patterns; Goldman Sachs' models also do not yet incorporate potential positive impacts from policy changes like the reconciliation bill which could accelerate account growth. In contrast, Citizens JMP analysts raised their price target to $117 from $110, maintaining a Market Outperform rating, underscoring the strong financial performance and positive outlook. HealthEquity is also pursuing growth through innovation, such as a new AI-powered claims adjudication system expected to enhance operational efficiency, and anticipates potential legislative tailwinds that could expand HSA access, though InvestingPro indicates the stock currently trades above its calculated Fair Value, while analyst targets range from $98 to $130.

Key Decisions for Investors

• Given HealthEquity's robust Q1 FY26 financial performance and improved guidance, contrasted with concerns over slowing organic HSA account growth, investors should carefully weigh the company's operational momentum against macroeconomic headwinds influencing account acquisition.
• Consider the divergent analyst outlooks, with Goldman Sachs at Neutral ($104 PT) citing growth moderation and Citizens JMP at Market Outperform ($117 PT) focusing on strong financials, alongside InvestingPro's indication that HQY may be trading above its Fair Value when assessing current positions.
• Monitor key catalysts including the tangible impact of new AI-driven products on operational efficiency and member satisfaction, the progress of potential legislative changes expanding HSA access, and any shifts in macroeconomic conditions or hiring trends that could alter HSA adoption rates.